Standard BioTools to Buy Treeline Biosciences in $460 Million All-Stock Deal
The acquisition aims to deploy capital behind a catalyst-rich oncology pipeline and an experienced drug-development team.
**Standard BioTools Inc. (LAB) agreed to acquire Treeline Biosciences Inc. in a $460 million all-stock transaction**, the company said Sunday, marking its largest strategic move since a 2023 portfolio overhaul.
The deal values Treeline at $460 million and is expected to close in the second half of 2026, subject to regulatory approvals and Standard BioTools stockholder consent. No cash consideration or exchange ratio was disclosed in the release.
**Standard BioTools framed the acquisition as the optimal path to maximize shareholder value**, citing Treeline’s diversified portfolio of precision medicines in oncology and a management team with a proven track record in drug development. "Over the last several months, our Board and management team conducted a comprehensive review of potential growth initiatives and determined that a combination with Treeline is the best path forward to maximize value for our shareholders," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Deploying our capital behind this team and pipeline gives our stockholders exposure to a catalyst-rich portfolio with significant potential for value creation in both the near- and long-term".
Treeline’s pipeline focuses on oncology and other high-value therapeutic areas, positioning the combined company to accelerate breakthroughs in drug development. The acquisition follows Standard BioTools’ strategic transformation, which included streamlining its portfolio and strengthening its balance sheet.
**The transaction echoes recent all-stock mergers in the biopharma sector**, where companies have sought to combine pipelines and extend financial runways. In March 2025, Alumis Inc. and ACELYRIN Inc. reaffirmed their all-stock merger to create a leading clinical-stage biopharma company in immune-mediated diseases, citing a strengthened balance sheet and diversified pipeline. Similarly, GlycoMimetics Inc. acquired Crescent Biopharma in an all-stock deal in October 2024, with a $200 million private placement to fund operations through 2027.
The Standard BioTools-Treeline deal is contingent on customary closing conditions, including regulatory and stockholder approvals. The company did not disclose expected accretion or integration synergies in the release.